Tamtam Try Tamtam free
ICU Medical logo

ICU Medical account plan

IV therapy safety solutions

At a glance

ICU Medical makes infusion systems, IV consumables and vital care products, with FY2025 revenues of $2,231.3 million and about 13,000 employees.

ICU Medical (Nasdaq: ICUI), founded in 1984 and based in San Clemente, California, develops, manufactures and sells infusion therapy, vascular access and vital care products: IV pumps and safety software, IV sets, needlefree connectors, catheters, closed system transfer devices, and respiratory, anesthesia, monitoring and temperature management products. It has approximately 13,000 employees in over 35 countries and customers in over 100 countries. FY2025 total revenues were $2,231.3 million, net income was $0.7 million and gross margin rose to 36.8%. Most global revenue comes from products made in Costa Rica and Mexico.

Business units

Strategic priorities

Gross margin expansion
A 43% gross margin target by the exit of 2027 is maintained; Q3 2026 gross margin was 41.9%.
Infusion pump platform
Grow Infusion Systems at least high single digits in 2026, file a revised 510(k) for the MedFusion 5000 syringe pump, follow with CADD, and use European authorization of Plum Duo and Solo.
Resolve FDA quality issues
Close out the 2025 FDA warning letter covering Medfusion 4000 and CADD Solis VIP, with $60 million to $80 million planned in 2026 for Smiths Medical restructuring, integration and quality spending.
Free cash flow and capital return
Year-to-date free cash flow reached $173 million against an original $150 million target; with net leverage at 2x, returning capital is under consideration for the new year.
Portfolio pruning in Vital Care
Exit unprofitable SKUs and certain Japanese surgical commodities, with several work streams on strategic outcomes for parts of Vital Care.

Latest results

Q3 2026 total revenues were $560.4 million against $537.0 million in Q3 2025 (presented on the call as $556 million, +5% organic), and net income was $26.8 million against a net loss of $3.4 million. Gross margin rose to 41.9% from 37.4%, helped by $10.4 million of IEEPA tariff refunds and price increases; adjusted EBITDA was $114 million and adjusted EPS $2.44 versus $2.03. U.S. revenue rose to $361.2 million while EMEA fell to $90.7 million. Full-year results are expected towards the higher end of $415 million to $435 million adjusted EBITDA and $8.60 to $9 adjusted EPS.

Investments and deals

IV Solutions joint venture
On May 1, 2025 ICU sold a 60% interest in IV Solutions to Otsuka Pharmaceutical Factory America for $211.2 million and keeps 40% of Otsuka ICU Medical LLC, which announced an over $500 million expansion of its Austin, Texas plant funded by OPF.
Capex
2026 capex now expected at about $75 million (previously $85 million to $100 million), covering Costa Rica, Europe, Mexico and U.S. plants and pumps placed outside the U.S.
Debt reduction
Term loans fell to $1.2 billion at September 30, 2026 after Term Loan B prepayments of $45.3 million (Q2) and $75.3 million (Q3).

Challenges and risks

Tariffs
Most products are made in Costa Rica and Mexico and imported into the U.S.; 2025 incremental reciprocal tariffs were $33.6 million, and the CFO warned that Section 232 tariffs could be hard to overcome for 2027 margins.
FDA warning letter and pump clearances
ICU withdrew its July 2025 510(k) applications for the new Medfusion and CADD pumps after FDA requested additional testing and plans to resubmit.
Vital Care decline
Vital Care fell 10% organic in Q3 2026, hit by the legacy Smiths logistics consolidation.
Input and logistics costs
A $10 per barrel oil rise costs about $3 million a year.

What leadership says

“the 43% started as 45%, it was net down 2% for tariffs.”

Vivek Jain, Chief Executive Officer and Chairman · Q3 2026 earnings call, November 5, 2026

“We know returning capital can be attractive on a thin share base, and our external M&A needs are minimal”

Vivek Jain, Chief Executive Officer and Chairman · Q3 2026 earnings call, November 5, 2026

“The market needs ICU Medical to be an innovative, reliable supplier”

Vivek Jain, Chief Executive Officer and Chairman · Q3 2026 earnings call, November 5, 2026

“We have a complete platform solution that will anchor this segment for the next 10-plus years as the product life cycles are incredibly long.”

Vivek Jain, Chief Executive Officer and Chairman · Q1 2026 earnings call, May 7, 2026

Where a supplier can help

Quality and regulatory support
The open FDA warning letter and the need for additional pump testing ahead of 510(k) resubmission favour testing, quality-systems and regulatory consulting suppliers.
Manufacturing cost and margin
The 43% gross margin target and tariff pressure make automation, procurement and plant efficiency offers for Costa Rica, Mexico and U.S. sites relevant.
Supply chain and tariff mitigation
Tariff exposure and the Smiths logistics consolidation that hit Vital Care create room for logistics, trade compliance and sourcing partners.
Pump rollout services
LVP pump competitive wins and rollovers, plus European launch of Plum Duo and Solo, need installation, training and integration services for hospital customers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like ICU Medical?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about ICU Medical

What does ICU Medical do?

It makes infusion therapy products (IV pumps and safety software), IV consumables such as sets, connectors and catheters, and vital care products for respiratory, anesthesia, monitoring and temperature management.

What is ICU Medical's revenue?

FY2025 total revenues were $2,231.3 million; Q3 2026 revenues were $560.4 million.

How many employees does ICU Medical have?

Approximately 13,000 employees in over 35 countries.

Who leads ICU Medical?

Vivek Jain is CEO and Chairman (since 2014), with CFO Brian Bonnell, COO Christian Voigtlander and President Daniel Woolson.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)